MFDA Lifts Ban on Indian Cough Syrup Following Safety Tests
The Maldives Food and Drug Authority (MFDA) has lifted its temporary suspension on Cofsy, a widely used cough syrup produced in India, following a month-long investigation into its quality.
In a statement issued today, the MFDA confirmed that laboratory tests on the affected batches of Cofsy had revealed no safety concerns. As a result, the import, sale, and consumption of the medicine is now permitted with immediate effect.
advertisement
advertisement
advertisement
advertisement
pic.twitter.com/fkRl4AggtC— MFDA (@MFDA_mv) September 29, 2024
The MFDA initially imposed the ban on August 19 after reports surfaced that “particles” had been found in the syrup. At the time, the agency assured the public it was conducting thorough tests to ensure the product’s safety before allowing its reintroduction to the market.
Cofsy, manufactured by India’s MMC Healthcare Ltd., is a combination medication used to treat cough with mucus and alleviate symptoms such as runny nose, sneezing, itching, and watery eyes.
For further information regarding the decision, the MFDA advises the public to contact their hotline at 7200321.
